France's competition authority has cleared Biogroup's acquisition of Laborizon, three months after the deal was announced. The pension fund backed lab group now owns around 20% of the for-profit market.
How do you add value to a business in a post COVID world - and are there any easy wins for new acquisitions? On Wednesday last week, an online audience heard HBI365's lively Q&A panel with with Ameos CEO Dr Axel Paeger, McKinsey partner Sebastian Sieler, and L Catterton managing partner Chinta Bhagat.
Cigna now describes itself as “a global health service company” rather than an insurer and has reorganised its European operations. Toor has recently been promoted to CEO Europe. He says that the insurer, which has 15% (US$840m) of its revenue in Europe, doesn't want to verticalise through owning primary care providers but wants instead to provide an end-to-end user experience.
Analyst forecasts suggest that healthcare sector valuations have been largely unaffected by the crisis, with EMEA hospitals and medtech stocks now being more expensive than before the Covid outbreak, both on an EBITDA and PE multiples basis.
UK lab group Viapath has been nationalised, after Guy's and St Thomas' and King's College Hospital NHS Foundation Trusts bought out its private sector partner Serco following the loss of a £2.25bn outsourcing contract in which Synlab remains the preferred bidder. Could Synlab's expected success be the first of a slew of new outsourcing contracts for big lab platforms? HBI talks to a consultant to find out more.
Regulatory body Public Health England (PHE) has ordered telehealth player Babylon to stop selling B2C antibody tests until it has established their accuracy. Supplier Abbott has already said that the test is not suitable for home sample collection but players are still scrambling to sell in what's likely to be a multi-billion market.
Will Covid-19 be a game changer for the lab sector? The prospect of big government contracts and a massive, unserved B2C market is drawing new players into the diagnostic lab sector. Could they have a permanent impact?